Phase I Open-Label, Dose-Escalation and Pharmacokinetic Study of Subcutaneous Prolanta in Subjects With Recurrent or Persistent Epithelial Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer

Trial Profile

Phase I Open-Label, Dose-Escalation and Pharmacokinetic Study of Subcutaneous Prolanta in Subjects With Recurrent or Persistent Epithelial Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer

Recruiting
Phase of Trial: Phase I

Latest Information Update: 15 Feb 2018

At a glance

  • Drugs HPRL G129R (Primary)
  • Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Focus Adverse reactions; First in man
  • Acronyms ProlantaOC
  • Sponsors Oncolix
  • Most Recent Events

    • 13 Feb 2018 Planned End Date changed from 1 Jan 2018 to 1 Feb 2019.
    • 13 Feb 2018 Planned primary completion date changed from 1 Dec 2017 to 1 Feb 2019.
    • 08 Jan 2018 According to an Oncolix media release, The first cohort, treated with the lowest dose, was completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top